Footwear giant Deckers Brands announced a 7.1% rise in Q3 FY26 net sales to $1.95 billion, driven by explosive growth from its HOKA running brand and solid gains from UGG, despite a challenging retail environment.
The Walt Disney Company has placed a $30 billion valuation on ESPN as part of its newly finalized strategic partnership with the National Football League, which includes complex future equity options and a major integration of NFL media assets.
While savings accounts offer safety and liquidity, experts warn that historically low interest rates are silently eroding purchasing power. We examine the risks of idle cash and explore strategies to protect—and grow—your nest egg.
The family of Milagros Ortiz demands accountability after a marked police cruiser, found at fault in a preliminary report, struck her car, leading to her death. An internal investigation is ongoing.
Ford Motor Company and Chinese tech giant Xiaomi have both denied a Financial Times report claiming preliminary discussions about producing Xiaomi's electric vehicles in the United States, as the auto industry navigates steep new tariffs on Chinese imports.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
Schweiter Technologies (SWTQ) has seen significant price swings on the SIX Swiss Exchange. With its current valuation trading well above industry peers, we examine whether the stock's optimistic growth prospects justify the premium or if investors should wait for a better entry point.
Lithia Motors' shares have retreated over 11% in the past year, sparking debate among investors. A detailed analysis of its discounted cash flow and peer comparisons suggests the auto retailer may be significantly undervalued, trading at a steep discount to its estimated intrinsic value.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
Ahead of the Singapore Airshow, GE Aerospace executives are contending with persistent supply chain disruptions and geopolitical headwinds that threaten to squeeze the flow of critical engine parts, testing the operational resilience behind the company's robust share price.
REV Group shares have skyrocketed nearly 7x over five years, leaving investors to grapple with a critical question: has the rally run its course, or does the specialty vehicle manufacturer still offer value at current levels? We examine the valuation debate through multiple lenses.
Shares of oil and gas producer Ovintiv (OVV) have posted robust gains over recent months, reigniting the debate over its true worth. While some models suggest a significant discount to fair value, its premium valuation multiples tell a more complex story.
Two Harbors Investment Corp. (NYSE: TWO) finds itself at a crossroads following a sharp single-day sell-off. While the mortgage REIT shows a significant discount to peers on a price-to-sales basis, underlying financials and conflicting valuation models leave investors questioning its true worth.
A new congressional report reveals major private student loan companies are aggressively expanding in anticipation of a borrower surge, driven by recent federal lending cuts, raising alarms among Democratic lawmakers about reduced competition and consumer risks.
As Michael Fiddelke steps into the CEO role, Target confronts a prolonged sales decline, intense competition, and escalating political tensions in its Minneapolis home base.
A landmark tripartite agreement aims to deploy up to 10GWh of battery storage across Europe, combining financial muscle, cutting-edge technology, and project development expertise to accelerate the continent's decarbonization efforts.
Citing a global rocket shortage and industry-wide bottlenecks, Amazon has formally requested the FCC to push back a key deployment deadline for its Kuiper satellite internet constellation by two years, highlighting the logistical challenges of competing with SpaceX's Starlink.
The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.
Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.
Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.
